Novel Approaches to Acute Myeloid Leukemia Immunotherapy
暂无分享,去创建一个
[1] S. Agaugué,et al. NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient , 2018, Haematologica.
[2] R. Galetto,et al. Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia , 2018, Leukemia & lymphoma.
[3] David A Scheinberg,et al. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. , 2018, Blood advances.
[4] H. Einsele,et al. CAR T-cells targeting FLT3 have potent activity against FLT3−ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib , 2018, Leukemia.
[5] K. Davis,et al. Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.
[6] Mithat Gonen,et al. Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia , 2018, The New England journal of medicine.
[7] B. Fox,et al. Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome , 2017 .
[8] D. Porter,et al. Treating Relapsed / Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells , 2017 .
[9] G. Marcucci,et al. Anti-IL1RAP/CD3 Bispecific Antibody (BsAb) Is a Promising Novel and Effective Therapy for Acute Myeloid Leukemia (AML) , 2017 .
[10] B. Fox,et al. Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies , 2017 .
[11] B. Wood,et al. Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial , 2017 .
[12] Chan Hyuk Kim,et al. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia , 2017, International journal of molecular sciences.
[13] H. Goossens,et al. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. , 2017, Blood.
[14] C. Brennan,et al. Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML. , 2017, Cancer cell.
[15] R. Collins,et al. Immune responses and long‐term disease recurrence status after telomerase‐based dendritic cell immunotherapy in patients with acute myeloid leukemia , 2017, Cancer.
[16] M. Subklewe,et al. Recent developments in immunotherapy of acute myeloid leukemia , 2017, Journal of Hematology & Oncology.
[17] C. Bloomfield,et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation , 2017, The New England journal of medicine.
[18] I. Flinn,et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.
[19] P. Sharma,et al. Phase IB/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML. , 2017 .
[20] K. Zhao,et al. Potential Efficacy of Human IL-1RAP Specific CAR-T cell in Eliminating Leukemic Stem Cells of Chronic Myeloid Leukemia , 2017 .
[21] M. Carroll,et al. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. , 2017, Blood.
[22] P. Pandolfi,et al. MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. , 2017, Blood.
[23] W. Klapper,et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia , 2017, The New England journal of medicine.
[24] Genee Y. Lee,et al. An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia. , 2017, Blood.
[25] D. Olive,et al. Kinetics of Cytotoxic Lymphocytes Reconstitution after Induction Chemotherapy in Elderly AML Patients Reveals Progressive Recovery of Normal Phenotypic and Functional Features in NK Cells , 2017, Front. Immunol..
[26] J. Gartner,et al. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. , 2016, The New England journal of medicine.
[27] D. Neuberg,et al. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions , 2016, Science Translational Medicine.
[28] M. Brenner,et al. CD7 CAR for the Treatment of Acute Myeloid and Lymphoid Leukemia , 2016 .
[29] A. Bagg,et al. Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells , 2016 .
[30] D. Neuberg,et al. Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma , 2016 .
[31] K. Yanagihara,et al. All-trans retinoic acid enhances cytotoxic effect of T cells with an anti-CD38 chimeric antigen receptor in acute myeloid leukemia , 2016, Clinical & translational immunology.
[32] C. Chuah,et al. CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia. , 2016, Cancer cell.
[33] R. Hills,et al. Expression of CD33 is a predictive factor for effect of Gemtuzumab Ozogamicin at different doses in adult acute myeloid leukemia , 2016, Leukemia.
[34] H. Dombret,et al. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. , 2016, The New England journal of medicine.
[35] P. Nguyen,et al. CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.
[36] A. Cambi,et al. CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses , 2016, The Journal of Immunology.
[37] K. Rezvani,et al. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells. , 2016, Cytotherapy.
[38] G. Ehninger,et al. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts , 2016, Blood Cancer Journal.
[39] P. Thall,et al. PR1 Peptide Vaccine Induces Specific Immunity With Clinical Responses In Myeloid Malignancies , 2016, Leukemia.
[40] Nicola D. Roberts,et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.
[41] N. Munshi,et al. A first-in-human phase I trial of NKG2D chimeric antigen receptor-T cells in AML/MDS and multiple myeloma. , 2016 .
[42] J. Guenot,et al. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia , 2016, Clinical Cancer Research.
[43] J. Tolar,et al. IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function , 2016, Clinical Cancer Research.
[44] M. Boyiadzis,et al. Generating Peripheral Blood Derived Lymphocytes Reacting Against Autologous Primary AML Blasts , 2016, Journal of immunotherapy.
[45] T. Schell,et al. T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients , 2016, Clinical Cancer Research.
[46] S. Grupp,et al. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies , 2016, Science Translational Medicine.
[47] L. Kanz,et al. Induction of NK Cell Reactivity Against Myeloid Leukemia By a Novel Fc-Optimized CD133 Antibody , 2015 .
[48] D. Scheinberg,et al. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1 , 2015, Nature Biotechnology.
[49] R. Kischel,et al. The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk , 2015, PloS one.
[50] R. Fanin,et al. Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors , 2015, Oncotarget.
[51] T. Fioretos,et al. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia , 2015, Proceedings of the National Academy of Sciences.
[52] W. Hiddemann,et al. T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment , 2015, Journal of Hematology & Oncology.
[53] Angel F. Lopez,et al. Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice , 2015, Haematologica.
[54] P. Low,et al. Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. , 2015, Blood.
[55] P. Moore,et al. A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates , 2015, Science Translational Medicine.
[56] Mahiuddin Ahmed,et al. Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential , 2015, Leukemia.
[57] I. Kerridge,et al. A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia , 2015, Leukemia & lymphoma.
[58] H. Rammensee,et al. Characterization of a bispecific FLT3 X CD3 antibody in an improved, recombinant format for the treatment of leukemia. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[59] A. Burnett,et al. The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse , 2015, Leukemia.
[60] M. Carroll,et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia , 2015, Leukemia.
[61] J. Lang,et al. Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents , 2015, Front. Immunol..
[62] K. Rezvani,et al. Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies , 2015, Front. Immunol..
[63] G. Danet-Desnoyers,et al. Anti-Leukemic Activity of Daratumumab in Acute Myeloid Leukemia Cells and Patient-Derived Xenografts , 2014 .
[64] K. Wittrup,et al. Pre-Targeted Radioimmunotherapy Employing a Recombinant Bispecific Antibody Using a Murine Xenograft Model of Human Leukemia , 2014 .
[65] Badrinath Roysam,et al. Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells. , 2014, Blood.
[66] M. Marcatti,et al. Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation , 2014, Leukemia.
[67] Chaoying Ma,et al. Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification. , 2014, International journal of clinical and experimental pathology.
[68] G. Kvalheim,et al. New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia , 2014, Cancer Immunology, Immunotherapy.
[69] G. Ehninger,et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia , 2014, Blood Cancer Journal.
[70] H. Dombret,et al. Contribution of CD39 to the immunosuppressive microenvironment of acute myeloid leukaemia at diagnosis , 2014, British journal of haematology.
[71] L. Weiner,et al. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. , 2014, Blood.
[72] K. Rezvani,et al. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia , 2014, Haematologica.
[73] M. Carroll,et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. , 2014, Blood.
[74] H. Ramshaw,et al. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC , 2014, Leukemia.
[75] B. Kuster,et al. Clec12a is an inhibitory receptor for uric acid crystals that regulates inflammation in response to cell death. , 2014, Immunity.
[76] Lei Gao,et al. Hypothesis: Tim-3/Galectin-9, A New Pathway for Leukemia Stem Cells Survival by Promoting Expansion of Myeloid-Derived Suppressor Cells and Differentiating into Tumor-Associated Macrophages , 2014, Cell Biochemistry and Biophysics.
[77] O. Mandelboim,et al. Immune evasion by oncogenic proteins of acute myeloid leukemia. , 2014, Blood.
[78] C. Blank,et al. Interferon‐induced programmed death‐ligand 1 (PD‐L1/B7‐H1) expression increases on human acute myeloid leukemia blast cells during treatment , 2014, European journal of haematology.
[79] R. Kischel,et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. , 2014, Blood.
[80] S. Parmar,et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents , 2013, Leukemia.
[81] L. Naldini,et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. , 2013, Blood.
[82] A. Scott,et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[83] Xiuli Wang,et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. , 2013, Blood.
[84] Jennifer G. Abelin,et al. MHC Class I–Associated Phosphopeptides Are the Targets of Memory-like Immunity in Leukemia , 2013, Science Translational Medicine.
[85] Jennifer G. Abelin,et al. MHC Class I–Associated Phosphopeptides Are the Targets of Memory-like Immunity in Leukemia , 2013, Science Translational Medicine.
[86] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[87] D. Scheinberg,et al. Targeting the Intracellular WT1 Oncogene Product with a Therapeutic Human Antibody , 2013, Science Translational Medicine.
[88] Thomas M. Schmitt,et al. Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients , 2013, Science Translational Medicine.
[89] B. Wood,et al. Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia , 2013, Haematologica.
[90] Z. Berneman,et al. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia , 2012, Leukemia.
[91] K. Döhner,et al. Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. , 2012, Blood.
[92] S. Ben-Neriah,et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. , 2012, Blood.
[93] D. Olive,et al. B and T Lymphocyte Attenuator Mediates Inhibition of Tumor-Reactive CD8+ T Cells in Patients After Allogeneic Stem Cell Transplantation , 2012, The Journal of Immunology.
[94] L. Palmqvist,et al. Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91(phox) expression and the PARP-1/PAR pathway of apoptosis. , 2012, Blood.
[95] H. Rammensee,et al. Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia , 2012, Leukemia.
[96] P. Crocker,et al. CD33‐related siglecs as potential modulators of inflammatory responses , 2012, Annals of the New York Academy of Sciences.
[97] R. Hills,et al. Expression of CD200 on AML blasts directly suppresses memory T-cell function , 2012, Leukemia.
[98] R. Solana,et al. Decreased expression of DNAM‐1 on NK cells from acute myeloid leukemia patients , 2012, Immunology and cell biology.
[99] D. Munn,et al. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? , 2011, Blood.
[100] Yi-xiang Han,et al. Elevated frequencies of CD4+CD25+CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia , 2011, International journal of cancer.
[101] A. Korman,et al. PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation. , 2011, Cancer research.
[102] P. Kloetzel,et al. The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed. , 2011, Blood.
[103] B. Bauvois,et al. Aminopeptidase‐N/CD13 is a potential proapoptotic target in human myeloid tumor cells , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[104] D. Munn,et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. , 2011, Blood.
[105] A. Sergeeva,et al. An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. , 2011, Blood.
[106] S. Eschrich,et al. Abstract 5111: Integrative phospho-proteomic and genomic analyses identify AXL as a potential biomarker and therapeutic target for NRAS-mutated melanoma , 2011 .
[107] E. Estey,et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[108] Jeanine J Houwing-Duistermaat,et al. High-throughput characterization of 10 new minor histocompatibility antigens by whole genome association scanning. , 2010, Cancer research.
[109] B. Quesnel,et al. In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors , 2010, Cancer Immunology, Immunotherapy.
[110] D. Saul,et al. A recombinant trispecific single‐chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting , 2010, British journal of haematology.
[111] H. Goossens,et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination , 2010, Proceedings of the National Academy of Sciences.
[112] D. Hart,et al. Development of a Wilms’ tumor antigen-specific T-cell receptor for clinical trials: engineered patient’s T cells can eliminate autologous leukemia blasts in NOD/SCID mice , 2010, Haematologica.
[113] A. Abo,et al. Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia , 2010, Haematologica.
[114] Federica Torri,et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. , 2009, The New England journal of medicine.
[115] J. Gribben,et al. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. , 2009, Blood.
[116] Martin A. Cheever,et al. The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research , 2009, Clinical Cancer Research.
[117] E. Thiel,et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. , 2009, Blood.
[118] R. Schlenk,et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. , 2009, JAMA.
[119] T. Whiteside,et al. Increased Frequency and Suppression by Regulatory T Cells in Patients with Acute Myelogenous Leukemia , 2009, Clinical Cancer Research.
[120] J. Esteve,et al. CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy , 2009, Leukemia.
[121] H. Salih,et al. Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans. , 2009, Cancer research.
[122] I. Bernstein,et al. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. , 2008, Blood.
[123] R. Fischer,et al. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes , 2008, Molecular Cancer Therapeutics.
[124] R. Berger,et al. Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies , 2008, Clinical Cancer Research.
[125] Yuqiang Ji,et al. Clinical significance of B7-H1(PD-L1)expression in human acute leukemia , 2008, Cancer biology & therapy.
[126] R. Schlenk,et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. , 2008, Blood.
[127] M. Labopin,et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[128] M. Baccarani,et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. , 2007, Blood.
[129] R. Hills,et al. CD200 as a prognostic factor in acute myeloid leukaemia , 2007, Leukemia.
[130] M. Pistillo,et al. CTLA‐4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis , 2007, British journal of haematology.
[131] S. Pileri,et al. Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase , 2007, Leukemia.
[132] S. Rosenberg,et al. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.
[133] J. Dick,et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells , 2006, Nature Medicine.
[134] Lieping Chen,et al. The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. , 2006, Experimental hematology.
[135] T. Lister,et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. , 2005, Blood.
[136] G. V. van Dongen,et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. , 2005, Blood.
[137] D. Scheinberg,et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[138] N. Schmitz,et al. Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies. , 2003, Blood.
[139] C. Uyttenhove,et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.
[140] H. Prentice,et al. Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function – implications for the adoptive immunotherapy of leukaemia , 2001, Clinical and experimental immunology.
[141] E. Ball,et al. Direct effect of bispecific anti-CD33 x anti-CD64 antibody on proliferation and signaling in myeloid cells. , 2001, Leukemia research.
[142] Wei Chen,et al. CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein. , 1998, Journal of immunotherapy.
[143] E. Thiel,et al. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. , 1995, Leukemia.
[144] K. Oshimi,et al. A bispecific antibody enhances cytokine-induced killer-mediated cytolysis of autologous acute myeloid leukemia cells. , 1993, Blood.
[145] W. Hiddemann,et al. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism , 2016, Leukemia.
[146] Ipilimumab for Patients with Relapse after Allogeneic Transplantation. , 2016, The New England journal of medicine.
[147] Quan-shun Wang,et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[148] R. Reibke,et al. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential. , 2010, Cellular immunology.
[149] Daniel Olive,et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. , 2007, Blood.
[150] M. Loken,et al. CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system. , 2006, Cytotherapy.
[151] J. Fisher,et al. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32). , 1992, Journal of hematotherapy.
[152] MYELOID NEOPLASIA Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment , 2022 .